149 related articles for article (PubMed ID: 38773088)
1. Priming with LSD1 inhibitors promotes the persistence and antitumor effect of adoptively transferred T cells.
Qiu F; Jiang P; Zhang G; An J; Ruan K; Lyu X; Zhou J; Sheng W
Nat Commun; 2024 May; 15(1):4327. PubMed ID: 38773088
[TBL] [Abstract][Full Text] [Related]
2. Ex vivo Akt inhibition promotes the generation of potent CD19CAR T cells for adoptive immunotherapy.
Urak R; Walter M; Lim L; Wong CW; Budde LE; Thomas S; Forman SJ; Wang X
J Immunother Cancer; 2017; 5():26. PubMed ID: 28331616
[TBL] [Abstract][Full Text] [Related]
3. Enhanced Cancer Immunotherapy by Chimeric Antigen Receptor-Modified T Cells Engineered to Secrete Checkpoint Inhibitors.
Li S; Siriwon N; Zhang X; Yang S; Jin T; He F; Kim YJ; Mac J; Lu Z; Wang S; Han X; Wang P
Clin Cancer Res; 2017 Nov; 23(22):6982-6992. PubMed ID: 28912137
[No Abstract] [Full Text] [Related]
4.
Hu X; Majchrzak K; Liu X; Wyatt MM; Spooner CJ; Moisan J; Zou W; Carter LL; Paulos CM
Cancer Res; 2018 Jul; 78(14):3888-3898. PubMed ID: 29769201
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of histone lysine-specific demethylase 1 elicits breast tumor immunity and enhances antitumor efficacy of immune checkpoint blockade.
Qin Y; Vasilatos SN; Chen L; Wu H; Cao Z; Fu Y; Huang M; Vlad AM; Lu B; Oesterreich S; Davidson NE; Huang Y
Oncogene; 2019 Jan; 38(3):390-405. PubMed ID: 30111819
[TBL] [Abstract][Full Text] [Related]
6. LSD1 inhibition sustains T cell invigoration with a durable response to PD-1 blockade.
Liu Y; Debo B; Li M; Shi Z; Sheng W; Shi Y
Nat Commun; 2021 Nov; 12(1):6831. PubMed ID: 34819502
[TBL] [Abstract][Full Text] [Related]
7. Phenotypic and functional attributes of lentivirus-modified CD19-specific human CD8+ central memory T cells manufactured at clinical scale.
Wang X; Naranjo A; Brown CE; Bautista C; Wong CW; Chang WC; Aguilar B; Ostberg JR; Riddell SR; Forman SJ; Jensen MC
J Immunother; 2012; 35(9):689-701. PubMed ID: 23090078
[TBL] [Abstract][Full Text] [Related]
8. CD28 costimulation provided through a CD19-specific chimeric antigen receptor enhances in vivo persistence and antitumor efficacy of adoptively transferred T cells.
Kowolik CM; Topp MS; Gonzalez S; Pfeiffer T; Olivares S; Gonzalez N; Smith DD; Forman SJ; Jensen MC; Cooper LJ
Cancer Res; 2006 Nov; 66(22):10995-1004. PubMed ID: 17108138
[TBL] [Abstract][Full Text] [Related]
9. Ex vivo culture with interleukin (IL)-12 improves CD8(+) T-cell adoptive immunotherapy for murine leukemia independent of IL-18 or IFN-gamma but requires perforin.
Macgregor JN; Li Q; Chang AE; Braun TM; Hughes DP; McDonagh KT
Cancer Res; 2006 May; 66(9):4913-21. PubMed ID: 16651448
[TBL] [Abstract][Full Text] [Related]
10. Simultaneous Inhibition of LSD1 and TGFβ Enables Eradication of Poorly Immunogenic Tumors with Anti-PD-1 Treatment.
Sheng W; Liu Y; Chakraborty D; Debo B; Shi Y
Cancer Discov; 2021 Aug; 11(8):1970-1981. PubMed ID: 33687985
[TBL] [Abstract][Full Text] [Related]
11. Ex vivo interleukin-12-priming during CD8(+) T cell activation dramatically improves adoptive T cell transfer antitumor efficacy in a lymphodepleted host.
Rubinstein MP; Cloud CA; Garrett TE; Moore CJ; Schwartz KM; Johnson CB; Craig DH; Salem ML; Paulos CM; Cole DJ
J Am Coll Surg; 2012 Apr; 214(4):700-7; discussion 707-8. PubMed ID: 22360982
[TBL] [Abstract][Full Text] [Related]
12. CD8 T cell priming in the presence of IFN-α renders CTLs with improved responsiveness to homeostatic cytokines and recall antigens: important traits for adoptive T cell therapy.
Hervas-Stubbs S; Mancheño U; Riezu-Boj JI; Larraga A; Ochoa MC; Alignani D; Alfaro C; Morales-Kastresana A; Gonzalez I; Larrea E; Pircher H; Le Bon A; Lopez-Picazo JM; Martín-Algarra S; Prieto J; Melero I
J Immunol; 2012 Oct; 189(7):3299-310. PubMed ID: 22925929
[TBL] [Abstract][Full Text] [Related]
13. PD-1 Expression during Acute Infection Is Repressed through an LSD1-Blimp-1 Axis.
Bally APR; Neeld DK; Lu P; Majumder P; Tang Y; Barwick BG; Wang Q; Boss JM
J Immunol; 2020 Jan; 204(2):449-458. PubMed ID: 31811020
[TBL] [Abstract][Full Text] [Related]
14. Indirect Impact of PD-1/PD-L1 Blockade on a Murine Model of NK Cell Exhaustion.
Alvarez M; Simonetta F; Baker J; Morrison AR; Wenokur AS; Pierini A; Berraondo P; Negrin RS
Front Immunol; 2020; 11():7. PubMed ID: 32117218
[TBL] [Abstract][Full Text] [Related]
15.
Suematsu M; Yagyu S; Nagao N; Kubota S; Shimizu Y; Tanaka M; Nakazawa Y; Imamura T
Front Immunol; 2022; 13():770132. PubMed ID: 35154098
[TBL] [Abstract][Full Text] [Related]
16. Transfer of in vitro-expanded naïve T cells after lymphodepletion enhances antitumor immunity through the induction of polyclonal antitumor effector T cells.
Tanaka T; Watanabe S; Takahashi M; Sato K; Saida Y; Baba J; Arita M; Sato M; Ohtsubo A; Shoji S; Nozaki K; Ichikawa K; Kondo R; Aoki N; Ohshima Y; Sakagami T; Abe T; Moro H; Koya T; Tanaka J; Kagamu H; Yoshizawa H; Kikuchi T
PLoS One; 2017; 12(8):e0183976. PubMed ID: 28854279
[TBL] [Abstract][Full Text] [Related]
17. Permissive expansion and homing of adoptively transferred T cells in tumor-bearing hosts.
Perez C; Jukica A; Listopad JJ; Anders K; Kühl AA; Loddenkemper C; Blankenstein T; Charo J
Int J Cancer; 2015 Jul; 137(2):359-71. PubMed ID: 25530110
[TBL] [Abstract][Full Text] [Related]
18. Dendritic cell internalization of α-galactosylceramide from CD8 T cells induces potent antitumor CD8 T-cell responses.
Choi DH; Kim KS; Yang SH; Chung DH; Song B; Sprent J; Cho JH; Sung YC
Cancer Res; 2011 Dec; 71(24):7442-51. PubMed ID: 22028323
[TBL] [Abstract][Full Text] [Related]
19. Co-Expression of miR155 or LSD1 shRNA Increases the Anti-Tumor Functions of CD19 CAR-T Cells.
Zhang J; Zhu J; Zheng G; Wang Q; Li X; Feng Y; Shang F; He S; Jiang Q; Shi B; Wang D; Cao Z; Wang J
Front Immunol; 2021; 12():811364. PubMed ID: 35046962
[TBL] [Abstract][Full Text] [Related]
20. B cells imprint adoptively transferred CD8
Smith AS; Knochelmann HM; Wyatt MM; Rangel Rivera GO; Rivera-Reyes AM; Dwyer CJ; Ware MB; Cole AC; Neskey DM; Rubinstein MP; Liu B; Thaxton JE; Bartee E; Paulos CM
J Immunother Cancer; 2022 Jan; 10(1):. PubMed ID: 35017148
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
